Key result
Semaglutide weekly offers the lowest cost of control to achieve HbA1c targets among GLP1RAs.
Why the study?
The economic impact and cost of control of different GLP1 receptor agonists in Saudi Arabia were not previously evaluated.
Does semaglutide provide a more favorable cost of control per patient per year compared to other GLP-1 receptor agonists in Saudi Arabia?
Does semaglutide provide a more favorable cost of control per patient per year compared to other GLP-1 receptor agonists in Saudi Arabia?
Semaglutide 1 mg once weekly is the most economically favorable GLP-1 receptor agonist for achieving HbA1c targets from a Saudi Arabian payer perspective.
Answers are grounded in this paper and cite their sources.
Semaglutide linked to lowest modeled cost of glycemic control among GLP1RAs in Saudi Arabia; leaves open real-world confirmation before practice change.
Objectives: To perform a cost of control analysis of glucagon like peptide-1 receptor agonists (GLP1RA) in Saudi Arabia (SA) and determine the economic impact of adopting GLP1RAs. Methods: A budget impact model that captures the cost of control model was constructed to simulate hypothetical patient on six treatment options: a current mix of 60% liraglutide and 40% dulaglutide, semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide. We estimated the relative amounts of SAR spend to achieve HbA1c targets (≤6.5% or < 7.0%). For each treatment option, annual treatment cost, proportion of patients achieving HbA1c targets, and cost to treat major adverse cardiovascular events (MACE) were aggregated to estimate the cost of control per patient per year (CCPPPY) over 5-year horizon (2021-2025). Probabilistic sensitivity analysis (PSA) was performed as a confirmatory analysis. Results: The CCPPPY to achieve HbA1c ≤ 6.5%/<7.0% using current mix, semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide were SAR 17,097/SAR 14,113, SAR 12,889/SAR 11,123, SAR 15,594/SAR 12,892, SAR 19,184/SAR 15,940, SAR 580,211/SAR 380,936, and SAR 246,570/SAR 143,759, respectively. The relative amounts of SAR spend to achieve HbA1c ≤ 6.5%/<7.0% relative to 1 SAR on semaglutide in case of adopting current mix, liraglutide, dulaglutide, exenatide, and lixisenatide were SAR 1.42/SAR 1.18, SAR 1.30/SAR 1.07, SAR 1.60/SAR 1.33, SAR 48.33/SAR 31.73, and SAR 20.54/SAR 11.97, respectively. These results were confirmed in the PSA. Conclusions: Semaglutide 1 mg once weekly was the most economically favorable GLP1RA; associated with the least CCPPPY, and amount of SAR spent to achieve HbA1c of ≤6.50%/<7.00% versus all other GLP1RAs.
No takes yet. Share an insight, caveat, or question.
Alkhatib et al. (2022) studied Diabetes. Semaglutide vs. Current mix, liraglutide, dulaglutide, exenatide, and lixisenatide was evaluated on Cost of control per patient per year (CCPPPY) to achieve HbA1c ≤ 6.5% or < 7.0%. Semaglutide once weekly was the most economically favorable GLP1RA, associated with the lowest cost of control per patient per year to achieve HbA1c targets versus all other GLP1RAs.
Synapse has enriched 10 related papers. Consider them for comparative context: